Merck KGaA’s share price has recovered over the past year, yet long term holders are still facing a loss over five years, while the current valuation checks send a mixed message rather than a clear bargain or clear overvaluation. The stock is down about 27.4% over five years, which raises the question of whether the recent rebound is just a partial recovery or a reset to a new trading range. Merck KGaA’s recent role through M Ventures in funding Remepy’s hybrid drug pipeline can support...

Sandoz and Henlius will collaborate on up to 10 biosimilars amid opportunity to capitalise on global biosimilar loss-of-exclusivities.

The latest round brings the total capital raised by Remepy to $62m.

Find insight on Hikma Pharmaceuticals, Novo Nordisk, Merck and more in the latest Market Talks covering health care.

Merck KGaA (MKGAF) delivers 4.1% organic sales growth in Q2 2026, driven by Life Science and Electronics, while raising full-year guidance.

Merck KGaA (ETR:MRK) reported accelerating organic sales and earnings growth in the second quarter of 2026, led by Life Science and Electronics, and raised its full-year outlook for sales, EBITDA pre and earnings per share. Group net sales rose 3.4% year over year to €5.434 billion. Organic sales g

Merck KGaA (MKKGY) delivered earnings and revenue surprises of -44.68% and +3.54%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?